Comparative evaluation of three JAK2V617F mutation detection methods

American Journal of Clinical Pathology

Volumn 128, Issue 5, 2007, Pages 865-874

  Frantz, Christine ^a   Sekora, Donna M ^a   Henley, Donald C ^b   Huang, Chih Kang ^c   Pan, Qiulu ^c   Quigley, Neil B ^b   Gorman, Eric ^c   Hubbard, Roger A ^b   Mirza, Imran ^a  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^b Molecular Pathology Laboratory Network Inc   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Allele specific PCR; AS PCR; Capillary electrophoresis; JAK2 mutation; Polyacrylamide gel electrophoresis; Restriction fragment length polymorphism; RFLP

Indexed keywords

JANUS KINASE 2; JAK2 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CAPILLARY ELECTROPHORESIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DIAGNOSTIC PROCEDURE; DNA ISOLATION; FEMALE; GEL ELECTROPHORESIS; GENE MUTATION; GENOMICS; HUMAN; MALE; MYELOPROLIFERATIVE DISORDER; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; ADOLESCENT; ALLELE; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ANALYTICAL EQUIPMENT; BLOOD; COMPARATIVE STUDY; ELECTROPHORESIS; EVALUATION; GENETICS; METHODOLOGY; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PREDICTION AND FORECASTING; REPRODUCIBILITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM ANALYSIS; CHILD; DNA MUTATIONAL ANALYSIS; ELECTROPHORESIS; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PREDICTIVE VALUE OF TESTS; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS;

EID: 36248961144     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/LW7Q3739RBRMBXXP     Document Type: Article

References (31)

1. Michiels JJ, De Raeve H, Berneman Z, et al. The 2001 World Health Organization and Updated European Clinical and Pathological Criteria for the Diagnosis, Classification, and Staging of the Philadelphia Chromosome-Negative Chronic Myeloproliferative Disorders. Semin Thromb Hemost. 2006;32:307-340.
2. Ugo V, Marzac C, Teyssandier I, et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol. 2004;32:179-187.
3. Hinshelwood S, Bench AJ, Green AR. Pathogenesis of polycythaemia vera. Blood Rev. 1997;11:224-232.
4. Radosevic N, Winterstein D, Keller JR, et al. JAK2 contributes to the intrinsic capacity of primary hematopoietic cells to respond to stem cell factor. Exp Hematol. 2004;32:149-156.
5. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
6. James C, Ugo V, Le Couedic J-P, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature. 2005;434:1144-1148.
7. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
8. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
9. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005;106:3370-3373.
10. Greiner TC. Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders. Am J Clin Pathol. 2006;125:651-653.
11. Steensma D. JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility. J Mol Diagn. 2006;8:397-411.
12. V617F mutation in myeloproliferative disorders by melting curve analysis using the LightCycler system. Arch Pathol Lab Med. 2006;130:997-1003.
13. Stevenson WS, Hoyt R, Bell A, et al. Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood. Pathology. 2006;38:336-342.
14. Murugesan G, Aboudola S, Szpurka H, et al. Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. Am J Clin Pathol. 2006;125:625-633.
15. McClure R, Mai M, Lasho T. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia. 2006;20:168-171.
16. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162-2168.
17. V617F mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia. 2006;20:1055-1060.
18. Lay M, Mariappan R, Gotlib J, et al. Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis. J Mol Diagn. 2006;8:330-334.
19. James C, Delhommeau F, Marzac C, et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia. 2006;20:350-353.
20. Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn. 2005;7:396-403.
21. Lippert E, Boissinot M, Kralovics R, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood. 2006;108:1865-1867.
22. Sidon P, El Housni EI, Dessars B, et al. The JAK2V617F mutation is detectable at a very low level in peripheral blood of healthy donors [letter]. Leukemia. 2006;20:1622.
23. V617F: prevalence in a large Chinese hospital population. Blood. 2007;109:339-342.
24. Biernaux C, Loos M, Sels A, et al. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood. 1995;86:3118-3122.
25. Bose S, Deininger M, Gora-Tybor J, et al. The presence of typical and atypical bcr-abl fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood. 1998;9:3362-3367.
26. Khwaja A. The role of Janus kinases in haemopoiesis and haematological malignancy. Br J Haematol. 2006;134:366-384.
27. Ma W, Kantarjian H, Verstovsek S, et al. Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour. Br J Haematol. 2006;134:340-350.
28. McLornan D, Percy M, McMullin MF. JAK2 V617F: a single mutation in the myeloproliferative group of disorders. Ulster Med J. 2006;75:112-119.
29. V617F and response to erythropoietin therapy. Cancer. 2006;106:1739-1743.
30. V617F in polycythemia vera. Cancer. 2006;106:631-635.
31. Villeval J-L, James C, Pisani DF, et al. New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients. Semin Thromb Hemost. 2006;32:341-351.